Railway Pension Investments Ltd Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Railway Pension Investments Ltd grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 174.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 318,770 shares of the medical research company’s stock after purchasing an additional 202,700 shares during the period. Thermo Fisher Scientific comprises about 2.1% of Railway Pension Investments Ltd’s portfolio, making the stock its 22nd biggest position. Railway Pension Investments Ltd owned about 0.08% of Thermo Fisher Scientific worth $154,610,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. Norges Bank acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $2,264,615,000. Soundwatch Capital LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $807,713,000. Flossbach Von Storch SE raised its stake in shares of Thermo Fisher Scientific by 93.0% in the second quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after acquiring an additional 1,314,182 shares in the last quarter. EdgePoint Investment Group Inc. boosted its holdings in Thermo Fisher Scientific by 282.5% in the second quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock valued at $536,450,000 after purchasing an additional 977,127 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Thermo Fisher Scientific by 58.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,293,264 shares of the medical research company’s stock worth $929,828,000 after purchasing an additional 843,267 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 1,058 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the transaction, the vice president owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This trade represents a 7.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Frederick M. Lowery sold 6,912 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the sale, the executive vice president directly owned 14,367 shares in the company, valued at $8,360,731.98. This trade represents a 32.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 149,271 shares of company stock worth $86,507,282. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 2.2%

Shares of TMO stock opened at $592.19 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $575.98 and its two-hundred day moving average is $510.56. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a market capitalization of $222.49 billion, a P/E ratio of 34.21, a price-to-earnings-growth ratio of 3.90 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter last year, the business earned $5.28 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has initiated a share repurchase plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TMO shares. Citigroup raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $580.00 to $660.00 in a research report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. TD Cowen raised their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Finally, Morgan Stanley increased their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $616.60.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.